Intersect Follows Leaders In ENT

Following the lead of ENT start-ups like Acclarent and Entellus Medical, Intersect ENT Inc. is introducing a line of stent like implants capable of performing the same role drug-eluting stents played in interventional cardiology. Intersect’s implants provide moderate structural support to tissue that has been cut or dilated through FESS or balloon sinuplasty. But the principal function of the implant isn’t propping open nasal passageways but rather delivering drugs. A trio of clinical studies conducted by the company has found the released steroids produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions.

Medical device start-ups, borrowing a playbook from cardiology, over the past decade have introduced an “interventionalization” of the ear, nose, and throat specialty. Acclarent Inc. burst onto the scene six years ago with the first interventional attempt to alleviate chronic sinusitis, the painful inflammation of the sinus cavities usually treated by medicines or painful endoscopic sinus surgery. Acclarent, of course, introduced Balloon Sinuplasty, providing otolaryngologists with an effective middle step between medication and serious surgery to treat chronic sinusitis in the frontal, sphenoid, and maxillary sinuses. (SeeAlso see "Acclarent: Can Balloons Open Sinuses and the ENT Device Market?" - In Vivo, 1 January, 2006..) Rather than remove the tissue, Acclarent’s balloons pushed open the nasal passageways. Acclarent established a $100 million per year business before being acquired by Johnson &Johnson’s Ethicon Inc. for $785 million, a sum that enriched its venture investors and energized the entire device industry. [See Deal] Fast follower Entellus Medical Inc. is advancing Acclarent’s approach of using balloons to open up nasal passageways by creating a line of tools that enabled physicians to perform the procedure in-office rather than just in the interventional suite. The company is currently building its business and hoping for an ultimate outcome similar to Acclarent’s. (SeeAlso see "Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy" - In Vivo, 1 June, 2011..)

In blazing a trail for medical device start-ups, Acclarent and Entellus established relationships within the ENT specialty, creating an avenue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.